UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934
(Amendment No. )
Filed by the Registrant x
Filed by a party other than the Registrant ¨
Check the appropriate box:
| ¨ |
Preliminary Proxy Statement |
| ¨ |
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ¨ |
Definitive Proxy Statement |
| x |
Definitive Additional Materials |
| ¨ |
Soliciting Material under §240.14a-12 |
EDGEWISE THERAPEUTICS, INC.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if
other than the Registrant)
| Payment of Filing Fee (Check the appropriate box): |
| |
| x |
No fee required. |
| |
|
| ¨ |
Fee paid previously with preliminary materials. |
| |
|
| ¨ |
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 6, 2024
Edgewise Therapeutics, Inc.
(Exact name of registrant as specified in its
charter)
| Delaware |
|
001-40236 |
|
82-1725586 |
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.) |
1715
38th St.
Boulder,
CO 80301
(Address of principal executive offices) (Zip Code)
(720)
262-7002
(Registrant’s telephone number, including
area code)
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):
| ¨ |
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) |
| ¨ |
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12) |
| ¨ |
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ |
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which
registered |
| Common
Stock, $0.0001 par value per share |
|
EWTX |
|
The
Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(d) Election of Directors
On May 6, 2024, the Board of Directors (the
“Board”) of Edgewise Therapeutics, Inc. (the “Company”) appointed Arlene Morris to serve (i) as a Class I
director, with a term expiring at the Company’s 2025 annual meeting of stockholders, (ii) as a member of the Audit Committee
of the Board (the “Audit Committee”), and (iii) as a member of the Compensation Committee of the Board (the “Compensation
Committee”), replacing Peter Thompson as a member of the Audit Committee and Compensation Committee. The appointment of Ms. Morris
is the culmination of a lengthy search process for a new director that commenced after Kenneth Harrison’s resignation from the
Board in June 2023.
Arlene Morris, age 72, has served as Chief Executive
Officer of Willow Advisors, a consultancy advising biotech companies on financing, strategy and business development, since 2015. Previously,
she spent over a decade leading public biotechnology companies. From 2012 to 2015, Ms. Morris served as Chief Executive Officer of
Syndax Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of an epigenetic therapy for
treatment-resistant cancers. Prior to this, she served as President and Chief Executive Officer of Affymax Inc., a biotechnology company.
She spent 15 years at Johnson & Johnson, a pharmaceutical company, in marketing, sales and senior level business development
positions. Ms. Morris is currently a member of the board of directors of Cogent Biosciences, since July 2019, Palatin Technologies, Inc.,
since June 2015, Viridian Therapeutics, Inc., since January 2018, and TC BioPharm (Holdings) PLC, since February 2022.
Ms. Morris received her B.A. in Biology and Chemistry from Carlow College.
The Board determined that Ms. Morris qualifies
as independent under the director independence standards set forth in the rules and regulations of the Securities and Exchange Commission
and the applicable listing standards of the Nasdaq Stock Market (“Nasdaq”) and that Ms. Morris also satisfies the additional
requirements of financial literacy and audit committee independence for Audit Committee service as well as compensation committee independence
for Compensation Committee service under the applicable rules and regulations of the SEC and the listing standards of Nasdaq.
There are no arrangements or understandings between
Ms. Morris and any other person pursuant to which Arlene Morris was selected as a director. In addition, there are no transactions
in which Ms. Morris has an interest that would require disclosure under Item 404(a) of Regulation S-K.
Ms. Morris will receive compensation for
her service pursuant to the Company’s outside director compensation policy. This includes an annual cash retainer of $40,000 per
year for service as an outside director, an additional cash retainer of $7,500 per year for service as a member of the Audit Committee,
and an additional cash retainer of $5,000 per year for service as a member of the Compensation Committee. Additionally, as a new outside
director, Ms. Morris was granted a stock option to purchase shares with a grant date fair value as determined in accordance with
U.S. generally accepted accounting principles equal to approximately $500,000. This stock option vests as to 1/36th of the total number
of shares on each monthly anniversary of the grant date, subject to Ms. Morris’ continued service through the applicable vesting
date. In the event of a Change in Control (as defined in the Company’s 2021 Equity Incentive Plan), the stock option will vest in
full. In addition, Ms. Morris also executed the Company’s standard form of indemnification agreement.
A copy of the press release announcing Ms. Morris’
appointment as a director is attached hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| EDGEWISE THERAPEUTICS, INC. |
|
| |
|
| By: |
/s/ R. Michael
Carruthers |
|
| |
R. Michael Carruthers |
|
| |
Chief Financial Officer |
|
Date: May 7, 2024
Exhibit 99.1
Edgewise Therapeutics Appoints Arlene Morris
to its Board of Directors
Boulder, Colo., (May 7, 2024) –
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment
of biotechnology industry veteran Arlene Morris to its Board of Directors. Ms. Morris has extensive experience in the pharmaceutical
and biotechnology industries serving in numerous executive management and board roles.
“With over 30 years of exceptional leadership
experience in the biotech industry, we are delighted to welcome Arlene to our Board,” said Kevin Koch, Ph.D., President and Chief
Executive Officer. “Arlene brings invaluable expertise in strategic development and operational excellence, and we are thankful
to count her as a valued advisor as we continue to advance our mission of changing the lives of patients and families affected by serious
muscle diseases.”
Ms. Morris currently serves as Chief Executive
Officer of Willow Advisors, a consultancy advising biotech companies on financing, strategy and business development. She brings extensive
experience in the pharmaceutical and biotechnology industries from numerous management and board roles. Previously, she spent over a decade
leading public biotechnology companies, as Chief Executive Officer of Syndax Pharmaceuticals, a biopharmaceutical company focused on the
development and commercialization of an epigenetic therapy for treatment-resistant cancers, and prior, as President and Chief Executive
Officer of Affymax, where she led the company through the development of peginesatide (Omontys®). Ms. Morris also held various
management and executive positions at Clearview Projects, Coulter Pharmaceutical, Scios, and Johnson & Johnson. She is currently
a member of the Board of Directors of Cogent Biosciences, Palatin Technologies, TC BioPharm and Viridian Therapeutics.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease
biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s
deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered skeletal
myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator
for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development.
The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases.
To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, X (formerly Twitter), Facebook, Instagram and Threads.
###
CONTACT:
Investors & Media
Michael Carruthers
Chief Financial Officer
ir@edgewisetx.com
Grafico Azioni Edgewise Therapeutics (NASDAQ:EWTX)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Edgewise Therapeutics (NASDAQ:EWTX)
Storico
Da Dic 2023 a Dic 2024
